Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying…
Read the full articleYou might also wanna read
This Stock Stumbled Last Year. Now It's the First Half's Best Performing Mega-Cap Healthcare Stock. Is It Too Late to Buy?
This company's recovery efforts are bearing fruit.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Why Is Accenture Stock Crashing, and is it a Buying Opportunity?
Investors are not convinced that Accenture can maintain its dominance amid the AI revolution.
Memory Stocks Take a Dive: Investors Rethink their AI Bets
As memory stocks tumble into bear market territory, investors are questioning if the sector's rapid growth can sustain itself in light of ge
Stock Market Selloff Raises Questions: AI Hype Unwind or Broader Growth Scare?
Stocks fell, the dollar surged, and bonds crept higher — the classic fingerprints of a growth scare. Is this selloff an unwind of AI hype or
Comments
Sign in to join the conversation.
No comments yet. Be the first.